Summary: Genmab has announced a new pre-clinical antibody program, HuMax-cMet, as well as a novel next generation antibody technology.

Genmab A/S (Copenhagen:GEN) will announce today at its Annual General Meeting a new pre-clinical antibody program, HuMax-cMet,as well as a novel next generation bispecific antibody technology.

HuMax-cMet is a fully human IgG1 antibody that targets the cMet oncogenicprotein. cMet is the receptor for hepatocyte growth factor, which is over-expressed or shows abnormal activity in a wide variety of solid tumors. HuMax-cMet may have the potential to treat a variety of solid cancers,including breast, lung, pancreatic, ovarian, prostate, renal, gastric andcolorectal.

HuMax-cMet was selected from a panel of over 75 unique human antibodies. HuMax-cMet targets the cMet protein at a unique site, binding strongly and showing anti-cancer activity in experimental laboratory and animal cancer models. Preparations for filing an IND to begin clinical trials are ongoing.

Bispecific antibodies combine the ability to bind two targets in a single molecule. This may result in more precise targeting and increased efficiency of disease killing mechanisms. Previous generations of bispecific technologies suffered from manufacturing difficulties and/or instability of bispecific molecules and also only remained in the body for a very short period of time. Genmab's novel proprietary bispecific antibody technology results in efficient generation of the desired type of bispecific antibodies. The new bispecific antibodies are human, stable and may remain in the body as long as regular human antibodies, giving the new bispecific antibodies more time to attack disease.

"We believe HuMax-cMet has great potential as a treatment for cancer. We also believe this novel antibody technology will further catalyze the development of novel antibody therapeutic approaches for cancer and other debilitating diseases," Said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

This Stock Exchange Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available onwww.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr;HuMax-IL8; HuMax-TAC; HuMax-HepC; HuMax-CD38; HuMax-CD32b; HuMax-TF;HuMax-Her2; HuMax-VEGF, HuMax-Wnt; HuMax-cMet and UniBody(R) are all trademarks of Genmab A/S. Arzerra is a trademark of GlaxoSmithKline.

Stock Exchange No. 13, 2010



CONTACT:  Genmab A/S

          Helle Husted, Vice President, Investor Relations

          +45 33 44 77 30

          Mobile: +45 25 27 47 13

          h.husted@genmab.com